A senior administration confirmed the move Monday evening, saying the White House believed there was “no clinical or medical reason” for the additional requirement.

At issue was the FDA's planned instruction that vaccine developers follow patients enrolled in their trials for at least two months to rule out safety issues before seeking emergency approval from the agency.

The White House action was first reported by The New York Times.

The intervention by Trump officials is the latest example of the administration undercutting its own medical experts working to combat the pandemic that has killed more than 210,000 Americans.

FDA Commissioner Stephen Hahn has been attempting to shore up public confidence in the FDA's vaccine review for weeks, vowing that career scientists, not politicians, will decide if the shots are safe and effective for mass vaccination.

But President Donald Trump has repeatedly insisted that a vaccine could be authorized before Election Day, even though top government scientists working on the administration's vaccine effort have stated that that timeline is very unlikely.

Last week seven former FDA commissioners blasted the administration for “undermining the credibility” of the FDA in a Washington Post op-ed and called for the release of the pending vaccine guidelines. The former FDA chiefs warned that public perceptions that a vaccine was rushed out for political reasons could derail efforts to vaccinate millions of Americans.

Beyond the damaging optics of overruling its own FDA, the practical impact of the White House move to block the guidelines could be relatively small.

Only one drugmaker, Pfizer, has suggested it could have data on the safety and effectiveness of its vaccine before Election Day. And a number of variables would still have to align for the company to submit, and the FDA to review and approve, a vaccine application before Nov. 3. Pfizer's competitors Moderna, AstraZeneca and Johnson & Johnson are working on longer researcher timelines.

Additionally, FDA scientists have been discussing the contents of the guidelines publicly for weeks and have made clear that the recommendations have already been shared with each of the vaccine developers.

The FDA released its initial expectations for COVID-19 vaccines in June. Among other metrics, the agency said any vaccine would have to be at least 50% protective against the virus. But the guidelines didn't spell out the conditions under which the FDA would use its emergency authorization powers to speed up the availability of a vaccine. Under emergency review, medical products face a lower standard that merely requires that their expected benefits outweigh their risks for use during a public health crisis.

The lack of specifics around using the emergency authorization for a vaccine became a flashpoint for outside experts, physicians and even politicians. FDA officials then began drafting a second guidance document with additional details.

Among other things, the guidelines would have made clear that any vaccine approved through the emergency pathway would still need to meet FDA’s preset safety and effectiveness standards. Instead, the expedited process would be used to bypass certain logistical and regulatory hurdles, such as the thousands of pages of manufacturing documentation normally required for a traditional vaccine application.

FDA emergency authorization for a vaccine would likely limit initial use to medical and other frontline workers, nursing homes and people most at risk of catching or becoming seriously ill from the virus. The vaccine would have to undergo review for full FDA approval, a monthslong process, before being approved for the general population

The FDA has faced criticism for allowing emergency use of some COVID-19 treatments backed by little evidence, but FDA officials have made clear that vaccines would face additional standards. Vaccines, unlike therapies, are given to healthy people and thus usually require more proof.

But Trump made clear last month that he was skeptical of any regulatory changes that might delay a vaccine’s authorization, even if those changes are aimed at increasing public trust.

The senior administration official, who spoke on the condition of anonymity to discuss the action, said the White House was intent on getting a safe vaccine to market and wanted to make sure “additional loopholes” weren't added that would slow down the process.

FDA spokespersons did not respond to requests for comment Monday night.

Read Also: Globe Biotech wants to make Covid vaccine available by Jan